Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. provides life sciences solutions focused on cold-chain sample management, automated storage, consumables, informatics, repository services and multiomics offerings. Its updates commonly cover the Sample Management Solutions and Multiomics businesses, including genomic services, gene synthesis execution, sample storage, high-throughput processing and branded products such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey.
Azenta news also includes quarterly operating results, guidance updates, long-range planning, governance and leadership changes, customer and research partnerships, and acquisition activity. The completed acquisition of UK Biocentre expanded the company’s sample management, sample storage and processing capabilities in the United Kingdom and added a European operational hub for its Sample Repository Services business.
Azenta (Nasdaq: AZTA) reported Q2 FY2026 continuing‑operations revenue of $145 million (1% YoY) and adjusted EBITDA of $7.8 million (5.4% margin). GAAP operating loss was $165.8 million, including a $149 million goodwill impairment. Fiscal 2026 revenue guidance is $603–$621 million; organic revenue now expected down ~2% to up 1% and long‑range plan extended to 2029.
Azenta (Nasdaq: AZTA) will announce fiscal second quarter 2026 results for the period ended March 31, 2026 on Wednesday, May 6, 2026 before market open. The company will host a conference call and live webcast on May 6 at 8:30 a.m. ET. A replay will be available beginning 8:30 a.m. ET on May 7, 2026. Webcast access: https://investors.azenta.com/events.
Azenta (Nasdaq: AZTA) named Trey Martin President of its Multiomics business, effective April 6, 2026, to accelerate execution of its Multiomics long-range plan and scale global gene synthesis capabilities. Ginger Zhou will step down as president and serve as an advisor through November 2026 to ensure continuity.
The move emphasizes operational excellence, commercial discipline, and profitable growth across Azenta's integrated Multiomics platform, with Martin reporting to CEO John Marotta and bringing extensive genomics and synthesis experience from Maravai and Danaher/IDT.
Azenta (Nasdaq: AZTA) acquired UK Biocentre Limited to expand biorepository and sample-management capabilities across Europe.
The deal consideration was GBP 20.5 million (net of cash, including up to GBP 1.8 million contingent). UK Biocentre had ~GBP 15.3 million revenue for the 12 months ended Sept 30, 2025. Azenta expects ~35bps dilution to 2026 Adjusted EBITDA margin and anticipates accretion to 2027–2028 organic revenue and margin targets. Azenta plans to deploy its 16-million-sample BioArc™ Ultra later in the year. A transaction webcast is scheduled for March 10, 2026.
Azenta (Nasdaq: AZTA) will participate in the Raymond James 47th Annual Institutional Investor Conference on March 3, 2026. Management will present beginning at 4:00 PM ET. A live webcast is available via the Azenta investor relations site and a replay will be posted after the event.
Azenta (Nasdaq: AZTA) announced a strategic partnership with Frontier Space to test sample management technologies in space as part of the EGGS-2 mission launched in January 2026.
The collaboration used 42 FluidX 0.26mL tubes in a custom container aboard Frontier's SpaceLab Mk 2 to evaluate thermal management, temperature monitoring, and tube durability under launch and spaceflight conditions.
Azenta (Nasdaq: AZTA) reported Q1 fiscal 2026 continuing operations revenue of $149 million, up 1% year-over-year, adjusted EBITDA of $13 million and non-GAAP diluted EPS of $0.09. Gross margin declined to 42.9%, down 380 basis points, while cash and marketable securities totaled $571 million.
The company entered a definitive agreement to sell B Medical Systems for $63 million and authorized a $250 million share repurchase program through 2028. Fiscal 2026 guidance: organic revenue growth of 3–5% and ~300 bps adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings for the period ended Dec. 31, 2025 on Wednesday, Feb. 4, 2026 before the market opens. The company will host a conference call and live webcast to discuss results on Feb. 4, 2026 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning Feb. 5, 2026 at 8:30 a.m. ET.
Azenta (NASDAQ: AZTA) signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for a purchase price of US$63 million. The sale is expected to close on or before March 31, 2026. Azenta described the divestiture as a step to simplify its portfolio and prioritize core capabilities, and said proceeds will be deployed to strengthen the company and support long-term value creation for shareholders. William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel.
Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.
The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.
Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.